세계의 글리코믹스 시장 예측(-2030년) : 제품별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Glycomics Market is accounted for $2.13 billion in 2023 and is expected to reach $6.61 billion by 2030 growing at a CAGR of 17.5% during the forecast period. Glycomics is a field of study within molecular biology and biochemistry that focuses on the comprehensive analysis of the structure, function, and biology of carbohydrates (sugars) in biological systems. It involves the study of complex carbohydrates, also known as glycans, and their interactions with other molecules in cells and organisms. Its research has far-reaching implications for understanding of biological processes, disease mechanisms, and the development of novel therapies.

According to a study published in February 2022 by researchers at the University of Copenhagen's Center for Glycomics, Heparin can now be produced without using animals through glycomics studies.

Market Dynamics:

Driver:

Increasing research in glycomics

Growing research in glycomics reveals the critical role of glycans in various biological processes, diseases, and therapeutic development. This broadening scope creates a wider market for glycomics technologies across biomedicine applications. Increased research in glycomics fosters innovation in analytical techniques. With increased research, there is a demand for more accessible and cost-effective glycomics technologies. It also creates a strong demand for specialized tools, technologies, and services. These aspects are propelling the market growth.

Restraint:

Limited standardization

Glycans are highly diverse and structurally complex molecules. Standardizing the analysis and characterization of glycans across different research settings and laboratories can be challenging, leading to potential inconsistencies and difficulties in data interpretation. In addition, its limited commercial standards, varied analytical techniques, environmental factors, structural diversity and evolutionary variabilites hinder the market demand.

Opportunity:

Rising cancer biomarkers and diagnostics

Glycomics research plays a crucial role in identifying specific glycan structures associated with various types of cancer. Understanding these unique glycan patterns allows for the development of accurate and reliable cancer biomarkers. It improves precision in cancer subtyping. Also, glycomics research may lead to the discovery of multiple glycan biomarkers associated with a specific cancer type. Combining these markers into a panel can further enhance diagnostic accuracy. Further, its practical implications for improving cancer detection, treatment, and patient outcomes are accelerating the market growth.

Threat:

High cost of instruments and reagents

Research labs, particularly those with limited budgets or in academic settings, may face challenges in acquiring and maintaining the necessary glycomics equipment and reagents. This can lead to a slower pace of research or even deter some labs from entering the field. The high cost of instruments and reagents may deter companies and manufacturers from investing in research and development for glycomics technologies. Therefore, the high cost of entry can potentially slow down the growth of the glycomics market.

COVID-19 Impact

The COVID-19 pandemic had both direct and indirect impacts on the field of Glycomics. Many research laboratories and institutions faced disruptions in their operations due to lockdowns, restrictions, and safety measures. The financial impact of the pandemic had a long-term effect on research funding. On the positive side, the pandemic highlighted the importance of understanding the role of glycans in viral infections. Researchers have explored the potential of glycans in the development of therapeutics, vaccines, or diagnostics related to COVID-19.

The kits segment is expected to be the largest during the forecast period

The kits segment is estimated to have a lucrative growth. Glycomics kits are specialized sets of reagents, tools, and protocols designed to facilitate the analysis and study of complex carbohydrates (glycans) in biological samples. They provide a standardized set of reagents and methods for the comprehensive profiling of glycans in biological samples. Glycomics kits include enzymes, labeling agents, and other tools necessary for the enzymatic release and modification of glycans, enabling detailed structural analysis. They play a crucial role in the diagnostics and quality control in biopharmaceuticals.

The drug discovery & development segment is expected to have the highest CAGR during the forecast period

The drug discovery & development segment is anticipated to witness the highest CAGR growth during the forecast period. The integration of glycomics into drug discovery and development processes leads to more precise and effective therapies, ultimately benefiting patients by improving treatment outcomes and minimizing side effects. Glycomics can contribute to the design of drugs with reduced off-target effects and improved selectivity. It can also improve vaccine efficiency. All these factors are driving the segment growth.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. North America, comprising the United States and Canada, represented one of the largest glycomics markets globally. North America is home to numerous prominent research institutions, universities, and academic medical centers. The region's advanced healthcare infrastructure, robust research ecosystem, and significant investments in biotechnology and life sciences contributed to the market's size and growth.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The Glycomics market in Asia Pacific includes a mix of global biotechnology companies, academic research institutions, and local manufacturers. Both established players and emerging start-ups contribute to the competitive landscape. The biopharmaceutical industry in Asia Pacific is expanding rapidly. The shift towards personalized medicine in the healthcare industry drives the demand for glycomics technologies in this region.

Key players in the market:

Some of the key players profiled in the Glycomics Market include: Asparia Glycomics, Merck KGaA, Bruker, Thermo Fisher Scientific, Inc, New England Biolabs, Waters Corporation, Takara Bio Inc, Agilent Technologies Inc., RayBiotech Life, Inc., Shimadzu Corporation, Danaher, Lectenz Bio, Intellihep Limited, Sanofi Corporation and Bayer AG.

Key Developments:

In August 2023, Thermo Fisher Scientific the world leader in serving science, announced the commercial launch of the EXENT® Solution, after receiving IVDR certification*. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies.

In June 2022, Sanofi announced the launch of its first Digital Accelerator to foster its ambition to become a leading digital healthcare company. The Accelerator will develop products and solutions that will support Sanofi's mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).

Products Covered:

• Kits
• Reagents
• Enzymes
• Instruments

Applications Covered:

• Diagnostics
• Drug Discovery & Development
• Other Applications

End Users Covered:

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Biopharmaceutical Companies
• Contract Research Organization (CRO)

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Glycomics Market, By Product

• 5.1 Introduction
• 5.2 Kits
  • 5.2.1 Glycan Labeling Kits
  • 5.2.2 Glycan Purification Kits
  • 5.2.3 Glycan Release Kits
  • 5.2.4 Other Glycomics Kits
• 5.3 Reagents
  • 5.3.1 Glycoproteins
  • 5.3.2 Monosaccharides
  • 5.3.3 Oligosaccharides
  • 5.3.4 Other Reagents
• 5.4 Enzymes
  • 5.4.1 Glycosidases
  • 5.4.2 Glycosyltransferases
  • 5.4.3 Neuraminidases
  • 5.4.4 Sialyltransferases
  • 5.4.5 Other Enzymes
• 5.5 Instruments
  • 5.5.1 High-Performance Liquid Chromatography (HPLC)
  • 5.5.2 Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight (MALDI-TOF)
  • 5.5.3 Mass Spectrometers
  • 5.5.4 Array Systems
  • 5.5.5 Other Instruments

6 Global Glycomics Market, By Application

• 6.1 Introduction
• 6.2 Diagnostics
• 6.3 Drug Discovery & Development
• 6.4 Other Applications

7 Global Glycomics Market, By End User

• 7.1 Introduction
• 7.2 Academic & Research Institutes
• 7.3 Pharmaceutical & Biotechnology Companies
• 7.4 Biopharmaceutical Companies
• 7.5 Contract Research Organization (CRO)

8 Global Glycomics Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Asparia Glycomics
• 10.2 Merck KGaA
• 10.3 Bruker
• 10.4 Thermo Fisher Scientific, Inc
• 10.5 New England Biolabs
• 10.6 Waters Corporation
• 10.7 Takara Bio Inc
• 10.8 Agilent Technologies Inc.
• 10.9 RayBiotech Life, Inc.
• 10.10 Shimadzu Corporation
• 10.11 Danaher
• 10.12 Lectenz Bio
• 10.13 Intellihep Limited
• 10.14 Sanofi Corporation
• 10.15 Bayer AG